Journals / Viral Hepatitis Journal / 2015 / Cilt: 21 - Sayı: 1

Kronik Viral Hepatitli Hastalarda Karaciğer Fibröz Derecesi ile Hyaluronik Asit, Tip 4 Kollajen ve Prokollajen Tip 3 Amino-Terminal Peptid Düzeyi İlişkisi

The Relationship of the Degree of Hepatic Fibrosis with Hyaluronic Acid, Type 4 Collagen, and Procollagen Type 3 N-Terminal Peptide Levels in Patients with Chronic Viral Hepatitis

Pages
8–12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It should not be forgotten that the basic diagnostic approach is liver biopsy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To investigate the relationship of liver histopathology with the levels of noninvasive markers, namely hyaluronic acid (HA) type 4 collagen and procollagen 3 amino-terminal peptide (P3NP) used for the assessment of hepatic fibrosis in patients with chronic viral hepatitis.
📊
Key Findings & Data:Materials and Methods: The study included 80 patients, 56 with chronic hepatitis B (CHB) and 24 with chronic hepatitis C (CHC) who presented to the outpatient clinic at Uludağ University Faculty of Medicine, Department of Gastroenterology, and underwent pretreatment liver biopsy between 2008 and 2010.
💡
Conclusion & Impact:It should not be forgotten that the basic diagnostic approach is liver biopsy.
🔬Design:Research Article
📍Scope:2008 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: To investigate the relationship of liver histopathology with the levels of noninvasive markers, namely hyaluronic acid (HA) type 4 collagen and procollagen 3 amino-terminal peptide (P3NP) used for the assessment of hepatic fibrosis in patients with chronic viral hepatitis. Materials and Methods: The study included 80 patients, 56 with chronic hepatitis B (CHB) and 24 with chronic hepatitis C (CHC) who presented to the outpatient clinic at Uludağ University Faculty of Medicine, Department of Gastroenterology, and underwent pretreatment liver biopsy between 2008 and 2010. The patients were divided into 2 groups according to the degree of fibrosis: group 1 included patients with grade &#8804;3 fibrosis (no fibrosis, mild or moderate), group 2 included patients with grade &#8805;4 fibrosis (severe fibrosis). The association of hepatic fibrosis grade with HA, type 4 collagen, and P3NP was examined. Results: Among the 65 patients in group 1 whose fibrosis grade was confirmed via liver biopsy, 47 (72.3%) had HBV and 18 (27.7%) had HCV, whereas 9 of 15 (60%) in group 2 had HBV and 6 of 15 (40%) had HCV. There was no significant difference in the non-invasive fibrosis markers between the groups (p>0.05). In addition, there was not a significant difference in HA and P3NP levels between the CHB patients in groups 1 and 2 (p>0.05), but the type 4 collagen level was significantly higher in the HBV patients in group 2 (p<0.05). On the other hand, there were no significant differences in HA, type 4 collagen, and P3NP levels, or fibrosis grade between the HC patients (p>0.05). Conclusion: The use of any marker or combination of markers examined in the present study is not a substitute for liver biopsy for assessing hepatic fibrosis. The fibrosis markers examined in the present study could be further examined in research on anti-fibrotic treatment. Future clinical investigations are needed for the evaluation of the value of these tests in diagnosis and monitoring. It should not be forgotten that the basic diagnostic approach is liver biopsy.

Özet

Amaç: kronik viral hepatitli hastalarda karaciğerdeki fibrozunu değerlendirmede noninvaziv belirteçlerden olan hyaluronik asit (HA), tip 4 kollajen, prokollajen 3 aminoterminal peptit (P3NP) düzeyinin karaciğer histopatolojisi ile ilişkisi araştırılmıştır. Gereç ve Yöntemler: Çalışmaya 2008-2010 tarihleri arasında Uludağ Üniversitesi Tıp Fakültesi, Gastroenteroloji polikliniğine başvuran tedavi öncesi karaciğer biyopsisi yapılan 56 HBV’ye bağlı ve 24 HCV’ye bağlı hepatit olmak üzere toplam 80 hasta alındı. Fibroz derecesine göre evre ≤3 olanlar grup 1 (fibroz yok, hafif veya orta), evre ≥4 olanlar grup 2 (ileri fibroz) olarak kabul edildi. Hastaların serum fibroz derecesi ile HA, tip 4 kollajen, P3NP düzeyi ile olan ilişkisi incelendi. Bulgular: karaciğer biyopsilerinde fibroz derecesine göre grup 1 olan toplam 65 olgunun 47’sinde (%72,3) hepatit B virüsü, 18’inde (%27,7) hepatit C virüsü, grup 2 olan 15 olgunun 9’unda (%60) hepatit B virüsü ve 6’sında (%40) hepatit C virüsü mevcuttu. Tüm olgularda serum fibroz belirteçleri HA, tip 4 kollajen, P3NP düzeyleri ile grup 1 ve 2 arasında anlamlılık saptanmadı (p>0,05). kronik hepatit B’de (kHB) HA, P3NP düzeyleri ile grup 1 ve 2 arasında anlamlılık saptanmadı (p>0,05). Ancak grup 2’de tip 4 kollajen düzeyleri anlamlı olarak yüksekti (p 0,05). Sonuç: Çalışılan gösterge veya göstergeler kombinasyonu, karaciğer fibrozunun ortaya konmasında henüz karaciğer biyopsisinin yerini tutamamaktadır. Fibroz belirteçleri, gelecek yıllarda antifibrotik tedavi için yapılacak klinik çalışmalarda çok önemli roller üstlenebilirler. Bu testlerin tanı ve tedavi izlemindeki değerinin belirlenmesi için başka klinik çalışmalara gereksinim vardır ve temel tanı yönteminin karaciğer biyopsisi olduğu unutulmamalıdır.

🔖

Cite This Article

IRAK, K., EMİNLER, A. T., AYYILDIZ, T., KESKİN, M., NAK, S. G., KIYICI, M., GÜREL, S., GÜLTEN, M., DOLAR, E. (2015). Kronik Viral Hepatitli Hastalarda Karaciğer Fibröz Derecesi ile Hyaluronik Asit, Tip 4 Kollajen ve Prokollajen Tip 3 Amino-Terminal Peptid Düzeyi İlişkisi. Viral Hepatitis Journal, Cilt: 21 - Sayı: 1, 8–12. https://ajindex.com/articles/332862

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Arhan M, köksal AŞ, Yüksel O, Akdoğan M. Significance of Serum Hyaluronic Acid Level in Assessment of Hepatic Fibrosis. Türkiye klinikleri J Med Sci 2007;27(1):21-6
  2. Curry MP Afdhal NH. Non-invasive markers of hepatic fibrosis. Rose BD (Editor). Wellesley (MA): Up TO date [CD ROM];2000
  3. Aydın Z, Demir k, Ökten A, kaymakoğlu S, Salmayenli N, Özdil S, karaca Ç, Danalıoğlu A, koroğlu G, Beşışık F, Boztaş G, Mungan Z, Çevikbaş U, Çakaloğlu Y. Assessment of non- invasive tests as marker of fibrosis in chronic viral hepatitis cases. İstanbul Üniversitesi Tıp Fakültesi Dergisi. 2003; 66:171- 177
  4. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005; 115:209-218
  5. Hui AY, Chan HL, Wong VW, Liew CT, Chim AM, Chan Fk, Sung JJ. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol. 2005; 100:616-623
  6. Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology. 2006; 43(Suppl 1):113-120
  7. Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, Ratziu V, Mercadier A, Benhamou Y, Hainque B. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol. 2004; 3:8. 8. kawada N. Molecular mechanism of stellate cell activation and therapeutic strategy for liver fibrosis. Comp Hepatol. 2004; 3(Suppl 1):3
  8. Zeremski M, Talal AH. Noninvasive markers of hepatic fibrosis: are they ready for prime time in the management of HIV/HCV co-infected patients? J Hepatol. 2005; 43:2-5
  9. Halfon P, Bourlière M, Pénaranda G, Deydier R, Renou C, Botta-Fridlund D, Tran A, Portal I, Allemand I, Rosenthal-Allieri A,Ouzan D. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol. 2005; 4:6
  10. Wong VS, Hughes V, Trull A, Wight DG, Petrik J, Alexander GJ. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepat. 1998; 5:187- 192
  11. Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling Rk, Su GL, Ghosh M, Wright EC; HALT-C Trial Group. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology. 2008; 47:789-798
  12. McHutchison JG, Blatt LM, de Medina M, Craig JR, Conrad A, Schiff ER, Tong MJ. Measurement of serum h